Trevi Therapeutics (TRVI) Q3 2026 earnings review
Trevi clears FDA path, but key trial readouts slip
Trevi Therapeutics, a biotech company developing the cough pill Haduvio, is spending faster as its clinical trials fill up, while its near-term milestones slipped into next year. Research and development costs rose 89% from a year ago to $19 million as a third study began recruiting, pushing the net loss to $21 million. Chief executive Jennifer Good secured FDA agreement on a fourth trial in lung-scarring cough, leaving $299 million in cash to fund operations into 2030.
| Cash and marketable securities | $299.4M $318.9M last quarter |
|---|---|
| Research and development expense | $19.1M +89% from a year ago |
| Net loss | $21.5M $11.8M a year ago |
| Cash runway outlook | Held into 2030 non-IPF ILD scope cut to Phase 2 |
⚖️ Verdict: 🔴 Bearish
The story got worse because near-term clinical readouts moved back and the cash budget now covers less work. Both the interim check on the refractory cough study and the start of the new lung-scarring study slipped into early 2027, and management quietly dropped Phase 3 of that lung-scarring program from its 2030 cash plan. On the positive side, the October FDA meeting cleared the regulatory path for that same Phase 2 study and a new patent extended protection to 2041.
The question now is whether running four global trials at once will force larger study sizes and higher cash burn. Either the slight delay in the refractory cough check is a minor site-opening lag, or high placebo responses will force an expansion of the trial by up to half. The interim sample-size decision early in the first quarter of 2027 will tell.
🐂 Bull Case
All Three Late-Stage Cough Trials Are Now Recruiting
Trevi Therapeutics is a drug developer testing one pill, Haduvio, for severe chronic cough. The drug targets idiopathic pulmonary fibrosis (IPF), a fatal lung-scarring disease, and refractory chronic cough (RCC), a cough lasting over eight weeks despite treatment. In the third quarter, the biotech firm started OCEAN-2, its second Phase 3 study in IPF cough. That means all three of its current trials are now enrolling patients across global clinical sites.
Starting OCEAN-2 on schedule keeps its main regulatory filing on track, because the US Food and Drug Administration (FDA) requires two successful Phase 3 trials for approval. The 12-week study still points to initial results in the second half of 2027, alongside the Phase 2b LAKE study in RCC. Meanwhile, the longer 52-week OCEAN-1 study remains on schedule for the first half of 2028.
What to watch: the announcement of 50% patient enrollment in the OCEAN-2 trial during the first half of 2027. Reaching the halfway mark on time would confirm that global clinical sites can recruit IPF patients without hitting bottlenecks.
FDA Agreed on the Second Lung-Scarring Cough Trial
Trevi also wants to treat chronic cough in patients with non-IPF interstitial lung disease (non-IPF ILD), a broader group of lung-scarring disorders affecting about 228,000 Americans. Until now, the regulatory path for this condition was unconfirmed because the company had only requested an agency meeting. In October 2026, Trevi met with the FDA and "gained overall alignment on the development path forward, including on the Phase 2 dose-ranging trial design".
The agreed study will test two twice-daily doses of Haduvio against a placebo in about 120 patients over 12 weeks. In addition, the US Patent and Trademark Office allowed a new patent "covering dosing nalbuphine ER in hepatically impaired patients with non-IPF ILD-related chronic cough" through 2041. Clearing the FDA hurdle removes the regulatory hold on this third disease target, while the patent extends protection by two years.
What to watch: first patient dosing in the non-IPF ILD Phase 2 study in the first quarter of 2027, following final FDA protocol review. Starting on time would prove the protocol passed final agency review without extra safety requirements.
Almost $300 Million Funds Trials Into 2030
Because Trevi has no approved products or sales, its cash balance determines whether it can finish its trials without selling more shares. Following a $162.3 million stock offering in April, the drug developer ended September with $299.4 million in cash and marketable securities. By our math, its net cash balance dropped by $19.5 million during the third quarter as the third clinical trial got underway.
The company said its cash will "provide cash runway into 2030 and fund the development of Haduvio for the treatment of patients with IPF-related chronic cough, through potential FDA approval". By our math, lasting until early 2030 allows an average cash burn of $22.2 million per quarter, or 14% above the third-quarter pace. That cushion spares investors from forced fundraising before the 2027 and 2028 trial readouts.
What to watch: quarterly cash and marketable securities in the fourth-quarter report. A quarterly cash drop staying near $22 million would show that starting the fourth trial keeps spending inside the 2030 budget.
Positives this quarter didn't test
Two standing positives from earlier quarters received no new figures in the third-quarter release.
- Lack of direct rivals in cough trials: after GSK stopped its rival cough program earlier this year, no competing late-stage data read out this quarter to challenge Haduvio's position.
- Doctor awareness campaign: the company gave no update on its educational outreach to lung specialists, which will be tested when commercial launch preparations begin closer to 2028.
🐻 Bear Case
Key Timelines Slipped and Cash Covers Fewer Trials
"This is an important time of clinical execution for Trevi as we actively open sites globally and enroll patients across all three active trials," chief executive Jennifer Good said. However, the third-quarter release delayed two near-term clinical milestones and quietly narrowed what the company's cash balance will pay for. Running three global studies at once is already stretching timelines before the fourth trial even starts.
- LAKE trial interim check: pushed from the fourth quarter of 2026 to early in the first quarter of 2027
- Non-IPF ILD trial start and readout: start moved from the second half of 2026 to the first quarter of 2027, pushing results from late 2027 to the first half of 2028
- Non-IPF ILD funding scope: cash now funds the program "through Phase 2", down from through Phase 3 in last quarter's filing
These shifts matter because the non-IPF ILD program is now a standalone Phase 2 dose-ranging study rather than an adaptive trial that rolls directly into Phase 3. Consequently, Trevi will need to run and pay for a separate Phase 3 trial later, which its current cash does not cover.
What to watch: the sample size re-estimation (SSRE) interim check for the LAKE study early in the first quarter of 2027. A decision to expand enrollment by up to 50% would raise research costs and push final results past the second half of 2027.
Trial Spending Nearly Doubled the Quarterly Loss
Opening clinical sites across three simultaneous studies is driving a steep rise in quarterly expenses. Trevi has no revenue, so every dollar spent on clinical trials and staff adds directly to its operating loss. In the third quarter, total operating expenses jumped 76.0% from a year ago to $24.5 million, up 19.4% from the second quarter alone.
Research and development (R&D) — the cost of running clinical trials and making drug supply — drove the increase, climbing 89.0% from a year ago to $19.1 million. By our math, R&D took up 77.9% of total operating expenses, up 5.4 percentage points from 72.5% a year earlier. Even with higher interest income on its cash, the quarterly net loss widened 81.8% to $21.5 million, and costs will rise again when the fourth trial begins.
What to watch: fourth-quarter R&D expense when the full-year report arrives in early 2027. A jump well above $20 million before the fourth trial even starts would pressure the 2030 cash horizon.
Risks this quarter didn't answer
Four standing risks from prior quarters had no new readings in the third-quarter release.
- Longer-term drug durability: prior IPF cough data only measured six weeks of treatment, and whether the benefit holds at 12 and 24 weeks will not be known until the Phase 3 readouts in 2027 and 2028.
- Placebo effect in the LAKE trial: patients in refractory cough trials often improve on placebo, a risk the early-2027 interim sample-size check will test.
- Future share dilution for commercial launch: the 2030 cash plan excludes marketing launch costs, Phase 3 RCC trials, and now Phase 3 non-IPF ILD trials.
- Single-source ingredient supply from a related party: the release gave no update on reliance on Par Health, chaired by a Trevi board member, for its active drug ingredient.
💲 Other KPIs
The share count rose 10.1% from a year ago and 2.0% from last quarter. Following the April 2026 stock offering, the higher share count spread the widening net loss across more shares, keeping the quarterly loss per share at $0.13 against $0.08 a year ago.
Interest earned on cash and marketable securities rose 43.6% from a year ago and 12.0% from the second quarter. The increase came from investing the April 2026 stock offering proceeds and offset about one-eighth of the quarter's operating expenses.
Working capital — short-term assets minus short-term bills — grew 57.4% from a year ago after the April stock sale, but fell 6.0% from $317.0 million in the second quarter as the US biotech firm spent cash on its three active clinical trials.
Overhead and administrative costs rose 41.5% from a year ago on higher staff and stock-compensation expenses, after climbing 35.9% in the first quarter and 23.6% in the second. From last quarter, overhead costs grew just 1.2%, keeping cash focused on clinical trials.
🔮 Guidance
Unchanged on time, narrowed on scope. The biotech company still expects its $299.4 million in cash and securities to last into 2030 and fund IPF cough through potential FDA approval. However, the plan now says cash will "enable the Company to fund the clinical development program through Phase 2 for the treatment of patients with non-IPF ILD-related chronic cough", whereas last quarter's filing included Phase 3.
Delayed. Trevi "now expects to report the outcome of the SSRE analysis early in the first quarter of 2027" instead of the fourth quarter of 2026. The check occurs once half of the patients finish treatment, and the company based the new date on current enrollment pace.
Delayed. Following its October 2026 FDA meeting, the company plans to start the 120-patient Phase 2 dose-ranging trial in the first quarter of 2027, pushing initial results from the second half of 2027 to the first half of 2028. It is the second delay for this study, which originally targeted a start in the first half of 2026.
Unchanged. Both the 12-week OCEAN-2 trial in IPF cough and the full Phase 2b LAKE trial in refractory cough remain scheduled to report initial results in the second half of 2027, despite the slight delay to LAKE's interim sample-size check.
Unchanged. The 52-week OCEAN-1 study in IPF cough, which started in the second quarter of 2026, remains on track to report initial results in the first half of 2028.
❓ Key Questions
Why does cash no longer cover Phase 3 for ILD?
Last quarter's filing said the $299 million cash pile funded non-IPF ILD through Phase 3, but this release says through Phase 2. Did the FDA require a separate Phase 3 trial, or are ongoing studies costing more than planned?
What slowed the LAKE trial's interim check to early 2027?
Management pushed the sample-size check from the fourth quarter of 2026 to early in the first quarter of 2027 based on projected enrollment. Why did management keep the full trial readout in the second half of 2027 if the halfway check slipped?
Why did OCEAN-2 target enrollment rise from 130 to 200?
Earlier filings listed 130 patients for OCEAN-2 before jumping to about 200 in the second quarter, and the third-quarter release omitted a patient target entirely. Is the larger size meant to test secondary symptoms or offset a weaker expected cough reduction?
Does Trevi have a backup supplier for its drug ingredient?
Trevi bought $2.4 million of its active ingredient in July from Par Health, whose chairman sits on Trevi's board. Will the third-quarter filing show any second supplier to remove single-source risk before Phase 3 finishes?